文献速递头颈部肿瘤放疗

调强质子治疗早期声门癌:高精度保护喉功能且治疗耐受性极佳

Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability.
PubMed 文献 · Radiat Oncol · 2022-12-05

本研究评估调强质子治疗(IMPT)作为T1-2N0声门鳞状细胞癌新型治疗选择,共分析2017至2020年间治疗的15例患者。中位总剂量70 Gy RBE(范围66-70 Gy RBE),1年和2年总生存率及无转移生存率均为100%,无高级别急慢性毒性,仅1例局部失败行挽救性喉切除术。

要点

  • 15例T1-2N0声门鳞癌患者接受IMPT,中位总剂量70 Gy RBE(范围66-70 Gy RBE)。
  • 1年和2年总生存率及无转移生存率均为100%,1例局部失败行挽救性喉切除术。
  • 无高级别急慢性毒性,每例患者平均CTCAE 1级和2级总体毒性事件数分别为4.1(95%CI 3.1-5.3)和1.0(95%CI 0.5-1.5)。

核心结论

  • 高精度质子治疗T1-2N0声门癌获得极佳的治疗耐受性、高喉功能保留率和有前景的肿瘤学结局。
  • IMPT有潜力成为早期喉癌患者的标准治疗选择。

研究设计与样本

  • 评估2017年至2020年间治疗的15例T1-2N0声门鳞状细胞癌患者,接受调强质子治疗(IMPT)。
  • 毒性按常见不良事件评价标准(CTCAE)v4.03记录。

主要发现

  • 多数为T1a/b肿瘤(66.7%),无患者有淋巴结或远处转移。
  • 中位总剂量为70 Gy RBE(范围66-70 Gy RBE)。
  • 1年和2年总生存率及无转移生存率均为100%。
  • 1例患者出现局部失败并接受挽救性喉切除术。
  • 未报告更高级别急慢性毒性;每例患者平均CTCAE 1级和2级总体毒性事件数分别为4.1(95%CI 3.1-5.3)和1.0(95%CI 0.5-1.5)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to the increasing expertise in transoral laser surgery and image-guided radiation therapy, treatment outcomes have recently improved in patients with early-stage glottic cancer. The objective of the current study was to evaluate intensity-modulated proton therapy (IMPT) as novel treatment option. METHODS: A total of 15 patients with T1-2N0 glottic squamous cell carcinoma, treated between 2017 and 2020, were evaluated. Toxicity was recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. RESULTS: The majority were T1a/b tumors (66.7%) and no patient had lymph node or distant metastases. The median total dose was 70 Gy relative biological effectiveness (RBE) (range 66-70 Gy RBE). The one- and two-year OS and metastases-free survival were 100%. One patient developed local failure and received salvage laryngectomy. No higher-grade acute or late toxicity was reported. The mean number of CTCAE grade I and II overall toxicity events per patient was 4.1 (95%-[confidence interval] CI 3.1-5.3) and 1.0 (95%-CI 0.5-1.5). CONCLUSION: High-precision proton therapy of T1-2N0 glottic cancer resulted in exceptional treatment tolerability with high rates of laryngeal function preservation and promising oncological outcome. IMPT has the potential to become a standard treatment option for patients with early-stage laryngeal cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Held T, Franke H, Lang K, et al. Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability. Radiat Oncol. 2022. PMID: 36471398. doi:10.1186/s13014-022-02144-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。